. Author manuscript; available in PMC: 2024 Jun 13.

Published in final edited form as: J Clin Virol. 2017 Mar 23;91:90–94. doi: 10.1016/j.jcv.2017.03.012

Table 1.

Paired comparison analysis of INSTI and other FDA-approved rapid tests (RT) using plasma specimens.

Rapid test	Results of a 2 × 2 table comparing a RT and INSTI

	NR/NR	NR/R	R/NR	R/R	p value

Determine Combo^a	102	2	34	92	<0.0001 ^*
Reveal G2/G3^b	134	14	1	80	0.0019 ^*
DPP HIV-1/2^a	134	15	2	79	0.0036 ^*
Statpak^a	135	20	1	74	<0.0001 ^*
Complete^a	135	22	1	72	<0.0001 ^*
Unigold^b	134	23	1	71	<0.0001 ^*
Oraquick^b	133	34	2	60	<0.0001 ^*

McNemar’s test was used to compare the performance of INSTI and other FDA-approved RTs using early HIV-1 infection from 26 seroconverters. Results from INSTI testing were compared to historical data using the same specimens tested with Determine HIV-1/2 Ag/Ab Combo rapid test (Determine Combo), DPP HIV1/2 assay (DPP HIV-1/2), Clearview HIV-1/2 STAT-PAK (Statpak) and Clearview HIV-12/Complete (Complete) (^an = 230) and with test OraQuick ADVANCE (Oraquick), Uni-Gold Recombigen HIV (Unigold), and Reveal G2 and G3 Rapid HIV-1 antibody test (Reveal) (^bn = 229). NR: non-reactive; R: reactive

statistically significant.